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Abstract
Background: Invasive pneumococcal disease (IPD) and pneumococcal pneumonia are common and carry a
significant morbidity and mortality. Current strategies to prevent pneumococcal disease are under review in the
United Kingdom (UK). We conducted a systematic review to evaluate the burden of vaccine type adult
pneumococcal disease specifically in the UK.
Methods: A systematic review conducted and reported according to MOOSE guidelines. Relevant studies from
1990 to 2015 were included. The primary outcome was the incidence of vaccine type pneumococcal disease,
focussing on the pneumococcal polysaccharide vaccine (PPSV), the 13-valent conjugate vaccine (PCV13) and the
7-valent conjugate vaccine (PCV7).
Results: Data from surveillance in England and Wales from 2013/14 shows an incidence of 6.85 per 100,000
population across all adult age groups for IPD, and an incidence of 20.58 per 100,000 population in those aged
>65 years. The corresponding incidences for PCV13 serotype IPD were 1.4 per 100,000 and 3.72 per 100,000. The
most recent available data for community-acquired pneumonia (CAP) including non-invasive disease showed an
incidence of 20.6 per 100,000 for adult pneumococcal CAP and 8.6 per 100,000 population for PCV13 serotype CAP.
Both IPD and CAP data sources in the UK suggest an ongoing herd protection effect from childhood PCV13
vaccination causing a reduction in the proportion of cases caused by PCV13 serotypes in adults. Despite this,
applying the incidence rates to UK population estimates suggests more than 4000 patients annually will be
hospitalised with PCV13 serotype CAP and more than 900 will be affected by IPD, although with a trend for these
numbers to decrease over time.
There was limited recent data on serotype distribution in high risk groups such as those with chronic respiratory or
cardiac disease and no data available for vaccine type (VT) CAP managed in the community where there is likely to
be a considerable unmeasured burden.
Conclusion: The most recent available data suggests that VT pneumococcal disease continues to have a high
burden in UK adults despite the impact of childhood PCV13 vaccination. IPD estimates represent only a fraction of
the total burden of pneumococcal disease.
Study registration: PROSPERO CRD42015025043
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Background
Streptococcus pneumoniae is a Gram-positive bacterium
and a commensal of the human nasopharynx [1]. Failure
of natural immunity to S. pneumoniae leads to pneumococ-
cal infection and in some cases to invasive pneumococcal
disease (IPD) [1–3]. The most frequent manifestation of
pneumococcal disease, however, is pneumococcal pneumo-
nia where the pneumococcus may be responsible for up to
60 % of cases of community-acquired pneumonia (CAP)
[4]. Hospitalised CAP carries a mortality rate of 5–15 % ris-
ing to more than 30 % in patients admitted to the intensive
care unit [5, 6]. The highest rates of pneumococcal disease
are observed in infants, the elderly, patients with chronic
respiratory disease and in patients with immune comprom-
ise [7–10]. This is despite the availability of effective anti-
microbial treatments against S. pneumoniae, emphasising
the importance of preventing pneumonia wherever possible
[11, 12]. The impact of pneumococcal disease in the UK is
substantial with approximately 6000 cases of IPD reported
annually and 192,281 hospital admissions for pneumonia in
2013/14 in England of which up to 50 % may be pneumo-
coccal [13, 14]. The cost to the UK National Health Service
is estimated at more than £1 billion [15].
Pneumococcal disease is, at least partially, a vaccine pre-
ventable disease. The 23-valent pneumococcal polysac-
charide vaccine (PPSV) has been recommended in the UK
for patients at high risk of pneumococcal disease since
2003, including adults over the age of 65 years. A system-
atic review and meta-analysis of the data supporting PPSV
show that it protects against IPD in adults in high income
countries (OR 0.20 95 % CI 0.10–0.39, n = 27886), but
limitations include uncertainty over its protection against
IPD in patients with chronic illnesses (OR 1.56 95 % CI
0.35–0.694 n = 3230), protection against non-invasive
pneumococcal CAP and its duration of protection [16].
The 13-valent pneumococcal conjugate vaccine (PCV13,
Prevenar-13) has been evaluated for the prevention of vac-
cine type IPD in children and in elderly subjects [17, 18].
The recent CAPITA trial conducted in the Netherlands
demonstrated the efficacy of PCV13 for the prevention, in
those aged ≥65, of vaccine type pneumococcal CAP and
also non-invasive CAP caused by vaccine serotypes [18].
An analysis based on the frequency of IPD and CAP caused
by S. pneumoniae in the Netherlands concluded that
PCV13 was cost-effective [19].
PCV13 is not currently part of the UK adult vaccin-
ation programme, neither for elderly patients aged
>65 years nor for specific high risk groups. Determining
whether PCV13 would be cost-effective in the UK re-
quires accurate information on the burden of vaccine
preventable pneumococcal disease in the UK.
We conducted a systematic review to determine the
incidence and burden of vaccine preventable pneumo-
coccal disease in the adult UK population.
Methods
This manuscript reports a systematic review of observa-
tional studies and was conducted and is reported accord-
ing to the MOOSE (meta-analysis and systematic review
of observational studies in epidemiology) guidelines
[20]. The review protocol was registered on PROSPERO
(CRD42015025043).
Search strategy
A librarian searched electronic databases from 1990 until
September 2015 for relevant studies using PUBMED and
EMBASE. A combination of text words and controlled vo-
cabulary terms related to the subject of interest (pneumo-
coccal disease) and possible outcome measures was used to
develop a sensitive search strategy. Terms entered were
(Streptococc* [tiab] OR pneumococc* [tiab]) AND (Sero-
type [Title/Abstract] OR serogroup [Title/Abstract) AND
(incidence OR frequency OR prevalence OR distribution).
Further searches were conducted for specific data on risk
groups and UK regions as described in the relevant sections
below. No language restrictions were applied to the search.
The search was supplemented by reviews of reference lists,
bibliographies and the investigators files where appropriate.
Inclusion criteria
The review included observational cohort studies (includ-
ing prospective, retrospective, registry and surveillance de-
signs) reporting any of the following study outcomes; 1)
Original data reporting of the incidence of vaccine type
and non-vaccine type pneumococcal disease; 2) Inclusion
or enrolment of patients in the United Kingdom; 3) Suffi-
cient data to generate or infer incidence of disease in the
general population or specific risk groups.
For data extraction, articles were independently
reviewed by two investigators. Non relevant studies were
excluded based on title and abstract review alone.
Outcomes
The primary outcome was the incidence of vaccine type
pneumococcal disease in the adult UK population,
expressed as an incidence per 100,000 population. Sec-
ondary measures included the proportion of pneumo-
coccal disease caused by PCV13 vaccine serotypes, other
vaccine serotypes and the proportion of cases of CAP
caused by vaccine serotypes was recorded. In addition
the proportion of cases of vaccine type pneumococcal
pneumonia in risk groups expressed as incidence per
100,000 population where possible. Risk groups include
patients with splenectomy, chronic respiratory disease,
chronic heart disease, chronic kidney disease and dia-
betes. Immunosuppression included any disorder leading
to significant immune suppression (whether inherited or
acquired) including HIV and iatrogenic immune sup-
pression (incl. chemotherapy and corticosteroids).
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Vaccine type pneumococcal disease
Vaccine type (VT) pneumococcal disease was defined as
being caused by one of the following serotypes: 4, 6B,
9 V, 14, 18C, 19 F, 23 F, 1, 3, 5, 6A, 7 F and 19A (PCV13
VT pneumococcal disease) OR pneumococcal disease
caused by one of the following serotypes: 4, 6B, 9 V, 14,
18C, 19 F, 23 F, 1, 3, 5, 7 F, 19A, 2, 8, 9 N, 10A, 11A,
12 F, 15B, 17 F, 20, 22 F and 33 F. (PPSV VT pneumo-
coccal disease).
Results were stratified according to the period of the
study, following PPSV introduction (2003), following
PCV7 introduction (2007) and following PCV13 intro-
duction (2010).
Results
The primary search identified 2,431 papers, with an add-
itional 51 papers identified from other sources. 38 co-
horts were eligible for inclusion. The characteristics of
the included studies are described in the online supple-
ment (Additional file 1: Tables E1-E5). The process of
literature review is summarised in Fig. 1.
Incidence of vaccine type pneumococcal disease in adults
in the UK
The most recent published data for the incidence of VT
pneumococcal disease is from 2013/14 in England and
Wales, reported by Waight et al. [21] This data is limited
to IPD.
Among all age groups (including children) PCV13 vac-
cine serotype IPD had an incidence of 1.40 per 100,000
population whilst PCV7 vaccine serotype IPD had an in-
cidence of 0.2 per 100,000 population [21].
The same authors reported that this represents a sta-
tistically significant reduction in PCV13 vaccine serotype
IPD compared to 2008–2010 (incidence 4.48 per
100,000 population), Incidence Rate Ratio (IRR) 0.31
(0.28–0.35) [21]. There was a corresponding increase in
non-vaccine serotypes from 4.19 per 100,000 to 5.25 per
100,000 during the same period, IRR 1.25 (1.17–1.35).
Regional data for the North East of England from 2006
to 2010 showed that PCV13 was responsible for 58 % of
IPD cases across all age groups with a reported inci-
dence of 7.8 per 100,000 falling to 5.2 per 100,000 in
2009/10. The corresponding figures for PCV7 serotypes
were 3.9 per 100,000 in 2006/7 falling to 1.3 per 100,000
in 2009/10 [22].
The contribution of PCV13 serotypes to total IPD was
relatively stable from 1996 to 2005, accounting for 76 %
of cases in 1996, and 69 % in 2005 in a study from the
Thames Valley region [23]. In the study of Waight et al.,
PCV13 serotypes accounted for 44.1 % of IPD across all
age groups (42.4 % among adults aged 15 years and
older) in 2008–10 falling to 20.4 % across all age groups
(20.8 % among adults aged 15+) in 2013/14 [21].
Data from Scotland has also been reported [24–27]. Fei-
kin et al. reported reductions in PCV7 serotypes following
the introduction of the childhood vaccination schedule in
2007, with an IRR of 0.90 (0.61–1.35) in year one, 0.58
(0.38–0.88) in year 2, 0.29 (0.17–0.50) in year 3 and 0.16
(0.08–0.34) in year 4 post vaccine introduction [27]. These
Fig. 1 Process of literature review. Abbreviations UK = United Kingdom, RCT = randomized controlled trial, Pn = pneumococcal VT = vaccine type
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reductions were equivalent to those reported in other
countries included in this analysis [27].
These data are limited to IPD. The search identified
few studies that addressed non-invasive pneumococcal
disease or that specifically addressed CAP. A series of
studies conducted in Nottingham UK prospectively re-
cruited patients admitted to hospital with CAP and used
a validated multiplex immunoassay to determine 14
pneumococcal serotypes in urine [28–30]. The study of
Rodrigo et al., which only included adults, found an inci-
dence of PCV13 serotype CAP of 21.7 per 100,000
population in 2008/2009 reducing to 8.6 per 100,000
population in 2012–2013 [29]. The corresponding rates
for PCV7 VT pneumococcal CAP was 11.1 per 100,000
in 2008/9 reducing to 2.3 per 100,000 in 2012–13 [29].
This was associated with a significant reduction in over-
all CAP from 90.7 cases per 100,000 in 2008/9 to 65.4
per 100,000 in 2012/13 [29]. This data is only applicable
to hospitalised cases of CAP as outpatients were not in-
cluded. Our systematic review identified no recent studies
of the incidence of VT CAP managed in the community.
In terms of PPSV vaccine coverage of IPD, the propor-
tion of pneumococcal disease cases caused by serotypes
present in the vaccine, has remained stable over time.
From 1995 to 1999, for those aged 5–64 years, 97.8 % of
isolates were covered by the PPSV vaccine [31]. The
study by Sleeman et al., identified slightly lower vaccine
coverage (89.9 %) in Oxford whilst in those aged
>65 years, vaccine coverage was 97.2 % [31]. Foster et al.
reported coverage of 91 % for PPSV serotypes for inva-
sive pneumococal disease in 1995 which remained stable
at 89 % in 2005 [23]. During the similar period of 1993–
1999 in Scotland, Kyaw et al. reported vaccine coverage
of 95 % in adults age 5–64 years and 96 % in those older
than 65 [32]. This remained stable over time, with
94.9 % coverage in 2003 from a Scottish study by Clarke
et al. [33] Andrews et al. reported the incidence of IPD
following the introduction of the PPSV programme to
all adults in 2003 [34]. From 1998 to 2004/5 they report
an incidence of 17.58 per 100,000 adults, with a stable
incidence of 17.95 per 100,000 in 2005/6 and 17.2 in
2006–2010, among those aged 65–74 years [34]. They
noted a small reduction in incidence of PPSV serotype
IPD following the introduction of PCV7 but not follow-
ing introduction of PPSV- IRR following PPSV in the
over 80’s was 0.99 (0.90–1.08) while following introduc-
tion of PCV7 the IRR was 0.77 (0.71–0.83) [28]. The in-
cidence rate remains substantial at 38.17 per 100,000
population in the over 80’s following PCV7 introduction
[34]. Regional data confirms these patterns, with data
from Hull and East Yorkshire (2002–2009) showing
89 % coverage for PPSV serotypes. This varied from
94.4 % in 2002 to 81.4 % in 2009, with the change arising
entirely due to reductions in PCV7 serotypes [35].
Burden of vaccine type pneumococcal community-
acquired pneumonia
The majority of studies only reported data for IPD, and
few specifically reported data for CAP. The only pro-
spective study to report data on the contribution of VT
pneumococcal CAP were from adults admitted to hos-
pital in Nottingham, UK from 2008 to 2013 [29].
The proportion of cases of CAP caused by S. pneumo-
niae extracted from Rodrigo et al. [29] and the propor-
tion of CAP cases caused by PCV7 and PCV13 are
shown in Fig. 2.
This study reported a decline over 5 years in the inci-
dence of all-cause CAP from 91 cases per 100,000 in
2008/9 falling to 65 cases per 100,000 in 2012/13.
Pneumococcal pneumonia declined over the same
period from 35 to 21 cases per 100,000 population. The
proportion of cases of pneumococcal pneumonia caused
by vaccine serotypes is shown below (Fig. 3). Overall,
PCV13 serotypes accounted for 41–62 % of pneumococ-
cal pneumonia during the study period, with the major-
ity of these cases caused by the additional serotypes in
PCV13 compared to PCV7 (namely 1,3,5,6A,7 F and
19A) [29]. This study found that only 13.3 % of pneumo-
coccal aetiology was identified by blood cultures, con-
sistent with comparison of population estimates which
suggest the incidence of non-invasive CAP is 5 to 10
fold higher than IPD. [21, 29] Interestingly, although
concerns have been raised that herd protection may not
reduce the incidence of serotype 3, this study showed a
marked reduction in serotype 3 CAP incidence from
2008 to 2013 [29].
The British Society for Antimicrobial Chemotherapy
(BSAC) reported surveillance data from respiratory tract
isolates of S. pneumoniae, although these represented
sputum specimens without a clear clinical diagnosis of
CAP [36]. Farrell et al. reported from 1997 to 2007 that
PCV13 serotypes accounted for 58.6 % of respiratory
tract isolates. The corresponding figure for PPSV was
approximately 72.2 %, accounting for some serotypes
not being reported as they were of low incidence [36].
Pneumococcal meningitis
Limited data were also available for pneumococcal men-
ingitis, with data from Johnson et al., showing that from
1998 to 2005, PCV13 serotypes accounted for 83.6 % of
cases of pneumococcal meningitis in England and Wales
[37]. PPSV serotypes accounted for 94 % of cases of
pneumococcal meningitis [37].
Absolute number of cases of PCV13 serotype CAP and
IPD
The most recent Office for National Statistics estimates of
the UK population are 54.3 m people in England, 64.5 m
people across the whole of the UK, with 11.4 m people
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aged >65 years [38]. Putting the incidence data into con-
text therefore, the most recent data would indicate that
934 cases of PCV13 serotype IPD would be expected in
adults per year [21]. This would include approximately
420 cases in patients aged >65 years [21]. Assuming the
results of Rodrigo et al. are applicable to the adult UK
population as a whole, there would be 10,696 hospitalised
cases of Pneumococcal CAP annually, with 4465 cases
due to PCV13 serotypes [29]. This would include an esti-
mated 2418 cases annually due to PCV13 serotypes in pa-
tients aged ≥65 years. There was no data to estimate the
number of non-hospitalised (outpatient) cases due to vac-
cine serotypes. These estimates are shown in Fig. 3. The
figure suggests that the true incidence from 2014/15 on-
wards is likely to be lower than reported above due to a
decreasing trend in absolute numbers with time.
Incidence of vaccine type pneumococcal disease in
specific risk groups in the UK
Adults aged >65 years
Among adults aged >65 years Waight et al. reported an
incidence of PCV13 serotype IPD of 10.33 per 100,000
population in 2008–10 reducing to 3.72 per 100,000 in
2013/14 [21]. PCV7 serotypes reduced from 4.58 per
100,000 in 2008–10 to 0.53 per 100,000 population in
2013/14, giving an IRR of 0.11 (0.08–0.18). This study
demonstrated a highly significant reduction in all 5 add-
itional serotypes while there were no significant reduc-
tions in the non-PCV13 serotypes [21].
From the study of Rodrigo et al., the overall contribution
of pneumococcal CAP to overall CAP incidence varied
from year to year from 17.1 to 37.3 % of cases [29]. The
proportion of cases due to PCV7 reduced substantially
Fig. 2 a Proportion of cases of adult hospitalised community-acquired pneumonia caused by S.pneumoniae, PCV7 serotypes and PCV13
serotypes respectively. b Proportion of pneumococcal CAP cases caused by different vaccine serotypes. Abbreviations. PCV = pneumococcal
conjugate vaccine, CAP = community-acquired pneumonia
Fig. 3 Projected number of patients affected by VT pneumococcal disease based on the most recent UK data identified in the systematic review
[21, 29]. PCV13 only CAP refers to serotypes contained in PCV13 that are not contained in PCV7. Abbreviations: CAP = community-acquired
pneumonia, IPD = invasive pneumococcal disease
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from 13.4 % of all CAP cases in 2008/9 to 0.3 % in 2011/12.
Rates of CAP due to PCV13 also reduced significantly from
2008/09 onwards, from 24.8 % of CAP cases to 7.5 % of
cases in 2011/12 and 12.6 % of cases in 2012/13 [29]. The
largest reductions were seen in those aged >85 years [29].
Risk groups
Van Hoek reported data on the impact of clinical risk fac-
tors for IPD in England [39]. The authors examined spe-
cific risk groups including those with asplenia, chronic
respiratory disease (including COPD), chronic heart dis-
ease, chronic renal disease, chronic liver disease, diabetes,
immunosuppression, cochlear implants and cerebrospinal
fluid leaks [39]. They used data from a 2009 survey of
PPSV uptake in general practice to estimate the propor-
tion of patients with these risk factors in England and
identified 44.8 % of patients aged >65 years having had at
least one risk factor, with chronic heart disease the most
common. [39] The incidence of IPD was greatly increased
in patients with risk factors, particularly chronic liver dis-
ease, immunosuppression and chronic respiratory disease.
In the older age group (>65 years), the incidence in pa-
tients without risk factors was 17.9 per 100,000, increasing
to 48 per 100,000 with one or more risk factor. This was
higher still at 91 per 100,000 if the co-morbidity was
COPD, and 129 per 100,000 in chronic liver disease [39].
A similar pattern was observed in younger adults (16–
64 years). The baseline incidence without risk factors
was 5.2 per 100,000, rising to 39 per 100,000 in risk
groups, with the higher incidence 172 per 100,000 in
those with chronic liver disease and 91 per 100,000 in
chronic respiratory disease. The study was conducted
prior to the introduction of PCV13. From 2005 to 2009,
there was good coverage of PPSV in the risk groups
(90 % in 2005/6 falling to 83 % in 2008/9, compared to
95 and 91 % in non-risk groups respectively), and also
good coverage of PCV13 (73 % of IPD cases in 2005/6
falling to 61 % in 2008/9, compared to 75 and 64 % over
the same period in non-risk groups) [39]. The introduc-
tion of PCV7 had a clear effect in both risk and non-risk
groups, with the % vaccine coverage falling from 45 % in
2005/6 to 21 % in 2008/9, with no significant differences
between risk and non-risk groups [39].
The search identified no specific data on the incidence
of non-invasive pneumococcal infection in risk groups
[10, 40–42]. A summary of the risk group incidence esti-
mates are shown in Fig. 4. Table 1 below summarises in-
cidence data from 3 studies with the most recent
incidence data for IPD, CAP and risk groups in the UK.
Immunosuppressed patients
There are few studies of pneumococcal disease in im-
munosuppressed patients and most surveillance data are
unable to identify these subgroups of patients. The
above study by Van Hoek identified that immunosup-
pression was the single greatest risk factor for IPD
among risk groups in the UK population [39]. The inci-
dence was 209 per 100,000 for immunosuppressed pa-
tients aged >65 years (odds ratio 11.7 compared to
patients >65 without immunosuppression). The equiva-
lent data for younger adults was 88 per 100,000 (odds
ratio 17.1 compared to adults 16–64 without immuno-
suppression [39]. HIV is also a risk factor for IPD. [42]
The above study identified an incidence of 95 per
100,000 in the elderly (age >65 years) although this is
based on only 2 cases. The incidence rate was 316 per
100,000 in adults aged 16–64 years (odds ratio 61.2
compared to patients without HIV) [39].
Yin et al. reported a study of IPD among HIV positive
individuals from 2000 to 2009. This included 63,109
HIV positive adults of which 951 developed IPD. [43]
This resulted in estimates of IPD incidence of 245 per
100,000 HIV positive adults. The study reported that in
the final year of data (2009), 23 % of causative serotypes
were covered by PCV7, a 54 % reduction compared to
prior to PCV7 introduction. For PPSV, the coverage was
89 % in 2000–2006 and 91 % in 2009 [43].
Impact of vaccine type pneumococcal disease on
outcomes
We identified minimal data on the pre-specified markers
of disease impact such as hospitalisation rates, length of
hospital stay, intensive care unit admissions, attributable
mortality and healthcare costs.
Van Hoek examined differences in site of infection and
mortality association with different vaccine serotypes in
England and Wales. Serotypes 35 F, 6C and 18C were
most frequently associated with meningitis in the elderly,
and serotype 1 was most strongly associated with empy-
ema hospitalisation [44].
The highest case fatality rates among patients aged 5–
64 years were reported for serotype 31 (33 %), 11A
(30 %) and 19 F (21 %). Serotype 31 is not included in
either the PPSV or PCV13, while 11A is included in
PPSV and not PCV13. Among the elderly (>65 years)
the highest case fatality rates were for serotypes 19 F
(41 %), 31 (40 %) and 3 (39 %) [44].
Scottish data was reported by Inverarity et al. for the
period 1992–2007. The highest 30-day mortality rate
was for serogroup 3 (24 %), followed by 19 and 23 (18
and 15 % respectively). Serotype data was not available
for the majority of the study [26].
Risk groups greatly influence the risk of mortality in
IPD. As reported by Van Hoek, the mortality in patients
aged >65 years without other risk factors was 29.1 %
(compared to 5.4 % in patients aged 16–64 years) [39].
Among the elderly, one or more risk factors increased
mortality by approximately 20 %, chronic heart disease
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increased risk by 40 %, kidney disease by 90 % and
chronic liver disease was associated with a near 3 fold
increased risk of death [39]. Even larger impacts were
seen in the younger age group, where having one or
more co-morbidity increased mortality by an odds ratio
of 3.9 (3.4–4.4) [39].
Discussion
Our systematic review identifies a high burden of
pneumococcal disease in adults in the UK, while also
revealing substantial ongoing changes in the epidemi-
ology of pneumococcal disease. The most recent data
from 2013/14 shows an incidence of 6.85 per 100,000
population across all age groups for IPD, and an inci-
dence of 20.58 per 100,000 population in those aged
>65 years [21]. The corresponding incidences for
PCV13 serotype IPD were 1.4 per 100,000 and 3.72
per 100,000. The most recent available data for CAP
including non-invasive disease showed an incidence of
20.6 per 100,000 for hospitalised adults with pneumo-
coccal CAP and 8.6 per 100,000 population for hospi-
talised PCV13 serotype CAP [21, 29]. We have
estimated that if these most recent estimates are ap-
plicable to UK population as a whole, there would be
at least 10,000 cases of hospitalised pneumococcal
CAP, with 4000 caused by PCV13 serotypes and more
than 900 cases of PCV13 serotype IPD. The estimates
of burden for non-invasive disease are likely to be an
underestimate due to the absence of data from CAP
managed in the community.
These data have limitations as discussed below, but
suggest that pneumococcal disease and PCV13 vaccine
type pneumococcal CAP continue to have a significant
burden in adults, even after the introduction of PCV13
in children.
Fig. 4 The most recent incidence data available for each pre-specified population grouped according to invasive pneumococcal disease and
community-acquired pneumonia. Data derived from Waight et al., Rodrigo et al. and van Hoek et al. [21, 29, 39]. The dates across the top indicate
the most recent year in which data were available
Table 1 Selected population IPD and CAP disease burden
estimates for PCV13 serotype CAP
Study Population Year Incidence/100,000
Waight et al [21] England and Wales
IPD – all ages
2013/14 1.40
Waight et al [21] England and Wales
IPD- age >65 years
2013/14 3.72
Rodrigo et al [29] Nottingham
(multicentre)
CAP- adults all ages
2012/13 8.60
Rodrigo et al [29] Nottingham
(multicentre)
CAP- Age >65 years
2012/13 16.75
Van Hoek et al [39] England
Risk groupsa Adult
2008/9 37.10b
Van Hoek et al [39] England
Risk groupsa ≥65 years
2008/9 39.84b
CAP refers to non-invasive and invasive pneumococcal community
acquired pneumonia
arisk groups include asplenia/splenic dysfunction/chronic respiratory disease/
chronic heart disease/chronic kidney disease/chronic liver disease/diabetes/
immunosuppression/cochlear implants/cerebrospinal fluid leaks [39]
bdata extracted based on reported 83 % coverage of total IPD incidence by
PCV13 during 2008/9
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There is, however, an ongoing trend of reduced inci-
dence of PCV13 serotype IPD and CAP in the UK, dem-
onstrated both in the study of Waight et al., who
demonstrated a 69 % incidence reduction between 2008
and 2014, and in the study by Rodrigo et al. who demon-
strated a reduction of 48 % in PCV7 CAP, and a 13 % re-
duction in the additional serotypes contained in PCV13
[21, 29].
Pneumococcal vaccination is now a core part of public
health policy [3, 45]. The pneumococcal polysaccharide
vaccination covers 23 common serotypes and has been
available since 1983. It was introduced into the routine
vaccination schedule in England and Wales in 2003/4
for patients aged 80 and over, followed by patients aged
75 and over in 2004/5 and all patients aged 65 and over
in 2005/6. The 7-valent conjugate vaccine was intro-
duced in children in 2007, followed by the introduction
of the 13-valent conjugate vaccine for children in 2010 [3].
S. pneumoniae is capable of causing IPD and non-
invasive pneumococcal pneumonia [46]. We identified a
large body of evidence on the incidence of IPD in the
UK thanks to ongoing surveillance programmes in Eng-
land, Wales and Scotland.
Patients aged >65 years have the highest incidence of
pneumococcal disease and non-invasive pneumococcal
pneumonia and are therefore the primary target of vac-
cination programmes [18]. Although high uptake of
paediatric conjugate vaccines has led to a reduction in
cases of adult IPD through herd protection, there re-
mains a substantial burden of IPD and pneumococcal
pneumonia in adults [47, 48].
The CAPITA trial was a randomized double blind pla-
cebo controlled trial conducted in the Netherlands
which demonstrated efficacy in the reduction of vaccine
type pneumococcal CAP in those adults >65 years re-
ceiving the 13-valent conjugate vaccine [18]. In the per-
protocol population, vaccine efficacy for the prevention
of a first episode of vaccine-type CAP was 46 %, and
protection persisted for at least 4 years. There are, how-
ever, important differences between the UK and the
Netherlands. The Netherlands has no PPSV programme,
while uptake of the PPSV vaccination in the UK is
among the best in Europe [45]. In addition, as noted
above, the PCV13 vaccine has been used in the UK since
2010 for children, while the CAPITA trial results were
obtained in a population where PCV7 was introduced
for newborns in 2006 and replaced by PCV10 in 2011
[49]. Therefore our data allows a degree of comparison
between the epidemiology of pneumococcal disease in
the UK and the Netherlands. In 2008 in the Netherlands,
68.4 % of IPD episodes in patients aged 65 years or older
were caused by PCV13 serotypes, compared to 42.3 % in
2013 [49]. The corresponding figures from Waight et al.
for England and Wales were 44.1 and 20.3 % [21].
Rodrigo et al. reported that 40.6 % of cases of pneumo-
coccal CAP were PCV13 VT in 2012/13 [29].
The impact of pneumococcal vaccination programmes
in children has been accompanied by a concern about
serotype replacement and the potential implication of
this on public health [50–52]. Waight et al. reported a
significant increase in non-vaccine serotype IPD follow-
ing the introduction of PCV13 (IRR 1.25 95 % CI 1.17–
1.35 comparing 2008–10 to 2013/14) [21]. Data re-
ported, only in abstract form to date, from the BSAC
surveillance project provides further evidence that this is
occurring [53]. Using data from up to 40 clinical labora-
tories in the UK and Ireland, they showed for bacter-
aemic pneumococcal disease, 76 % of cases were PCV13
serotypes prior to PCV7 introduction (data from Jan 04-
Dec 06) falling to 21 % (Jan-Dec 14). The corresponding
data for respiratory isolates was 59 % falling to 17 %
[53]. The most frequent serotypes for both bacteraemia
and lower respiratory tract infection in 2004–6 were
covered by PCV13, but in 2014 were not, with serotypes
8, 22 F and 12 F being most frequent in bacteraemia and
15A and 23B most frequent in LRTI [53]. They report
associated significant increases in penicillin, tetracycline
and multidrug resistance which appears to be mostly
due to expansion of serotype 15A [53]. Antimicrobial re-
sistance is an increasing problem in CAP generally and
these data emphasise the importance of ongoing surveil-
lance and consideration of the indirect impact of child-
hood vaccination [50–52, 54].
This study identified important gaps in the literature
regarding the burden of pneumococcal disease in the
UK. There was limited data outside of surveillance of
IPD. Data for non-invasive pneumococcal pneumonia
was limited to hospitalised patients in a single UK city,
in Nottingham, England and a series of respiratory tract
isolates forming part of the British Society for Anti-
microbial Chemotherapy surveillance studies [31, 36, 53]
which would include patients with CAP, but would also
include respiratory/sputum isolates from patients with
other respiratory tract infections such as exacerbations
of COPD [55], bronchiectasis (where S. pneumoniae can
be a coloniser) [56] and upper airway commensals.
There are important differences both in terms of sero-
types responsible for invasive vs non-invasive disease, in
disease outcomes and in vaccine effectiveness against
non-invasive disease vs invasive disease. Inclusion of
additional data on non-invasive CAP in the UK would
be valuable. Our available data suggests that there are
up to 10 cases of non-invasive pneumococcal CAP for
each case of IPD and so studies restricted to IPD are
likely to greatly underestimate the burden of pneumo-
coccal disease.
None of the studies identified in the systematic review
were conducted in the community and so the burden of
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pneumococcal disease in the community is unknown.
Multiple studies suggest that S. pneumoniae remains the
most common cause of CAP in outpatients, where the
majority of CAP is managed [57–60]. Although the mor-
tality rate of CAP in the community is low at less than
1 %, the impact is significant at a population level in
terms of lost days of work, reduced productivity and
long term complications [60, 61]. More data on the bur-
den of disease in the community is needed, as hospital
based studies may underestimate the true impact.
At the other end of the severity spectrum, we identi-
fied little data on the pneumococcal vaccine serotypes
associated with the most severe pneumonia causing in-
tensive care unit admission. Although Van Hoek et al.
reported data on the mortality attributable to different
serotypes using record linkage, similar data for ICU ad-
mission was not available [39]. Mortality and severe
pneumonia requiring ICU admission are not necessarily
synonymous as the majority of pneumonia related
deaths occur outside the ICU with up to 50 % occurring
due to co-morbidities rather than directly due to pneu-
monia [61–63].
The incidence of CAP, and pneumococcal disease in
particular is greatly increased in at risk populations such
as patients with COPD, chronic heart failure and im-
munosuppression [42]. COPD patients have a greatly in-
creased frequency of pneumonia at 22.4 per 1000 person
years due to a combination of reduced local immunity,
co-morbidities and the impact of immunosuppression
through inhaled corticosteroids [64, 65]. Additional risk
factors identified through analysis of UK health records
include diabetes, chronic heart disease, chronic renal dis-
ease, asplenia, chronic liver disease, sickle cell disease,
HIV, previous stroke, rheumatoid arthritis, Parkinson’s
disease, multiple sclerosis, dementia, osteoporosis and ma-
lignancy [66]. IPD data suggests a greatly increased risk of
IPD in patients with one or more risk factors, particularly
chronic liver disease, COPD and immunosuppression with
evidence of “risk stacking” with the incidences greatest in
patients with more risk factors, or a combination of in-
creasing age and high risk co-morbidities [39]. Mortality
from IPD is also greatly increased in patients from high
risk groups, ranging from a 20 % increase in risk of death
among elderly patients with COPD, to an estimated
1000 % increased risk of death among patients aged 16–
64 years with chronic liver disease, compared to patients
of the same age without liver disease [39].
The UK population is ageing, and therefore the burden
of CAP and pneumococcal disease in general is expected
to increase even with the impact of childhood and adult
vaccine programmes.
There are important regional variations in the inci-
dence of CAP in the UK. Millet et al. demonstrated a
significantly lower incidence of LRTI and CAP in
London and the South East of England compared to the
North, Yorkshire and the Midlands in both men and
women [67]. This may be partly explained by differences
in socioeconomic deprivation which is a major risk fac-
tor for CAP. Given the large differences observed in this
study between regions, estimates of risk averaged across
the whole of the UK should be interpreted in the local
context. [67]
Conclusion
VT pneumococcal disease continues to have a significant
burden in adults in the UK. IPD data will underestimate
the impact of pneumococcal disease because the major-
ity of cases of CAP are non-invasive. Nevertheless, both
IPD and CAP data sources in the UK suggest an ongoing
herd protection effect from childhood PCV13 causing a
reduction in the proportion of cases caused by PCV13
serotypes in adults. Despite this, the most recent data
suggests that PCV13 serotypes account for 12.6 % of all
cases of CAP and 41 % of pneumococcal CAP. This data
will be useful in evaluating the clinical and economic
case for adult PCV13 vaccination in the UK.
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